Introduction
Apoptosis is a conserved mechanism of cell death controlling the development and homeostasis of multicellular organisms. A family of cytosolic proteases, the caspases, stored in most cells as zymogens, plays an essential role in the execution of apoptosis. Proteolytic cleavage activates the initiating zymogen, which in turn triggers sequential proteolytic activation of each successive procaspase in the apoptosis cascade Salvesen and Dixit, 1997; .
Caspase 3 activation has been said to be critically important for the enactment of this apoptotic pathway (Porter and Janicke, 1999; Samali et al., 1999) . Caspase 3 is among the caspases (also including caspases 6 and 7) that are activated after disruption of the barrier function of the mitochondrial membrane (Marzo et al., 1998) . Thus, unlike the case for the so-called cytoplasmic caspases, which play a role in mitochondrial membrane permeabilization (Susin et al., 1997; Marzo et al., 1998; Medema et al., 1997) , caspase 3 activation depends critically on prior mitochondrial membrane disruption and its attendant release of the intermembrane protein cytochrome c (Susin et al., 1999; Scadi et al., 1998) . Once activated, caspases 3 and 7 have been shown to act on mitochondria to further disrupt their integrity (Chandler et al., 1998) , thus engaging in a self-amplifying feedback loop in which mitochondrial membrane permeabilization causes caspase activation and vice versa. In addition, apoptosis is regulated by Bcl-2 family proteins, including anti-apoptotic proteins such as Bcl-2 and Bcl-X L , and pro-apoptotic proteins such as Bax and Bak (Merry and Korsmeyer, 1997) . Current evidence suggests that Bcl-2 acts upstream of caspase 3 activation, at the level of cytochrome c release, to prevent apoptosis (Shimizu et al., 1996; Chinnaiyan et al., 1996; Kluck et al., 1997; Yang et al., 1997) .
Interestingly, MCF-7 human breast carcinoma cells do not express caspase 3 . Despite this, MCF-7 cells undergo morphological apoptosis after treatment with a variety of agents and conditions (Oberhammer et al., 1993; Eck-Enriquez et al., 2000) . We have previously shown that bcl-2 transfection shifts the concentration-response curve of MCF-7 cells to NCS in the direction of protection from apoptosis induction (Schor et al., 2000) . In the present study, we demonstrate by both morphological and physiological criteria apoptosis induction in mock-and bcl-2-transfected MCF-7 cells and determine the caspases and changes in regulatory protein expression involved in apoptosis induction and enactment in bcl-2-transfected MCF-7 cells treated with the antineoplastic agent, neocarzinostatin (NCS).
Results

Induction of apoptosis by NCS in MCF-7 cells
Our previous studies had demonstrated that the EC 50 for apoptosis induction by NCS in bcl-2-transfected MCF-7 cells is shifted approximately twofold in the direction of protection over mock-transfected cells (Schor et al., 2000) . As shown in Figure 1a , treatment with 5 nM NCS (1 h) induced apoptosis in almost 7% of mock-transfected MCF-7 cells by 24 h after treatment. At this concentration, MCF-7 cells transfected with bcl-2 were completely protected from NCSinduced apoptosis.
In contrast, 50 nM NCS universally induced cell death in both mock-and bcl-2-transfected MCF-7 cells. In both transfectants, 4 h after 50 nM NCS treatment, most cells exhibited membrane blebbing by light microscopy (data not shown), and condensed, fragmented nuclei on staining with propidium iodide (PI; Figure 1b ). Twenty-four hours later, most of the cells were detached from the culture¯ask surface.
Cytochrome c release in NCS-treated bcl-2-transfected MCF-7 cells Cytochrome c release is a critical component of the apoptotic process. It occurs upstream of caspase activation, and is inhibited by bcl-2 overexpression (Shimizu et al., 1996; Chinnaiyan et al., 1996; Kluck et al., 1997; Yang et al., 1997) . Nonetheless, our previous data suggested that the eects of bcl-2 transfection are quantitative rather than qualitative, and result in a shift in the threshold for induction, rather than an absolute block, of apoptosis (Schor et al., 2000) . We examined NCS-treated, bcl-2-transfected MCF-7 cells for the release of cytochrome c from their mitochondria. Starting at 15 min after NCS (50 nM) treatment, cytochrome c was released from the mitochondria into the cytosol, and it continued to be released for at least 24 h after completion of NCS treatment (Figure 2 ).
Increased levels of Bax and decreased levels of Bcl-2 after NCS treatment of MCF-7 cells Bcl-2, Bcl-X L and Bax expression are regulators of apoptosis (Merry and Korsmeyer, 1997) . Caspase 3-induced cleavage of Bcl-2 has been reported to accompany and facilitate apoptosis in caspase 3-expressing cells (Cheng et al., 1997) . In fact, we have demonstrated paradoxical potentiation of NCS-induced apoptosis in bcl-2-transfected, caspase 3-expressing PC12 pheochromocytoma cells (Cortazzo and Schor, 1996) . It is not clear how cells (like MCF-7 cells) that do not express caspase 3 bypass the eects of endogenous or transfection-induced Bcl-2 and undergo apoptosis. We therefore studied the levels of Bcl-2, Bcl-X L and Bax in mock-and bcl-2-transfected MCF-7 cells during NCS-induced apoptosis.
As is shown in Figure 3a , in both transfectants, starting at 10 min after NCS (50 nM) treatment, Bcl-2 protein levels were decreased. This decrease continued for at least 24 h after NCS treatment. It is not clear whether this represents down-regulation of the endogenous and/or, in the case of bcl-2-transfectants, exogenous bcl-2 gene or altered post-transcriptional protein handling. Bax protein levels were increased with a similar time course (Figure 3a) . Immuno¯uor-escent staining con®rms these results (Figure 3b ). In contrast, there was no correlation between Bcl-X L levels and NCS-induced apoptosis in mock-or bcl-2-transfected MCF-7 cells (data not shown). P53 and P21 in NCS-treated MCF-7 cells 5In other systems, the up-regulation of the tumor suppressor gene, p53, and consequent up-regulation of p21 waf1cip1 presages the onset of apoptosis. In both MCF-7 transfectants, however, there was no detectable P53 under either control or NCS-treated (5 nM or 50 nM) conditions (data not shown). P21 was not detected in native cells of either transfectant, but was detected in both transfectants 2 h after NCS treatment and up-regulated for 24 h after treatment (Figure 3a) . A simultaneously run lysate of A431 cells, known to express P53 (Santa Cruz Biotechnology) and stained with the same antibody, gave a robust band at 53 kD (data not shown).
Caspase inhibitors and NCS-induced apoptosis in MCF-7 cells
To determine the caspases (and therefore the alternate pathway) involved in apoptosis enactment in NCStreated MCF-7 cells, we treated mock-and bcl-2-transfected MCF-7 cells with selective caspase inhibitors beginning 2 h prior to treatment with NCS (50 nM). For freely cell permeable caspase inhibitors, concentrations of 10 and 25 mM were used; for poorly cell permeable caspase inhibitors, concentrations of 10 and 100 mM were used. In all cases, at this concentration of NCS, results obtained for mock-transfectants were indistinguishable from those obtained for bcl-2-transfectants. Results are therefore shown only for bcl-2-transfectants.
As shown in Figure 4a , b and c, respectively, Ac-AAVALLPAVLLALLAP-YVAD-CHO, which inhibits caspase 1 and 4, Ac-AAVALLPAVLLALLAP-IETD-CHO, which inhibits caspase 8 and granzyme B, and Z-WEHD-FMK, which inhibits caspases 1, 4 and 5, did not have any protective eect on NCS-treated MCF-7 cells at either concentration used.
Knowing that MCF-7 cells do not express caspase 3, and having shown that inhibition of caspases 1 and 4 did not alter NCS-induced apoptosis, Z-VAD-FMK and Ac-VAD-CHO, which inhibit caspases 1, 3, 4 and 7, were used to test the eects of inhibition of caspase 7 on NCSinduced apoptosis. As shown in Figures 5a and b , respectively, at a concentration of 100 mM, both of these compounds protected MCF-7 cells from NCS-induced apoptosis. Z-VAD-FMK was somewhat more potent in this regard, and inhibited apoptosis at 10 mM as well.
In addition, Figure 5c and d demonstrate that both Ac-AAVALLPAVLLALLAP-VEID-CHO, which inhibits caspase 6, and Ac-AAVALLPAVLLALLAP-LEHD-CHO, which inhibits caspases 4, 5 and 9, had protective eects upon NCS-treated MCF-7 cells, indicating the likely involvement of caspases 6 and 9 (caspases 4 and 5 having been shown not to be involved) in this process.
Sequential activation of caspases 6, 7 and 9 in NCS-treated MCF-7 cells
To de®nitively determine the temporal sequence of caspase activation in this pathway, we examined the activation of caspases 6 and 9 over time using a chromogenic substrate for each. As shown in Figure 6 , caspase 9 activity was elevated 15 min after NCS treatment in NCS (50 nM) -treated bcl-2 transfectants. The activity reverted to baseline by 1 h after treatment. In contrast, caspase 6 activity did not rise signi®cantly until 2 h after treatment, and had not yet peaked 6 h after NCS treatment.
The timing of caspase 7 activation was determined by Western blotting using an antibody that detects the active cleavage product of procaspase 7. As shown in Figure 7 , caspase 7 activation begins 1 h after and persists for at least 6 h after the completion of treatment.
Discussion
Breast carcinoma cells of the MCF-7 line have lost expression of caspase 3 as a result of a 47 base-pair deletion within exon 3 of the casp-3 gene. The deletion results in the skipping of exon 3 during pre-mRNA splicing, and thereby blocks translation of the casp-3 mRNA (Janicke et al., 1993) . Despite the absence of detectable caspase 3, native, mock-, and bcl-2-transfected MCF-7 cells have been shown to undergo apoptosis induced by a variety of stimuli (Oberhammer et al., 1993; Eck-Enriquez et al., 2000) . In agreement with this ®nding, the present study demonstrates that mockand bcl-2-transfected MCF-7 cells undergo apoptosis after treatment with the enediyne antineoplastic agent, NCS. MCF-7 cells treated with NCS (50 nM) exhibit typical apoptotic characteristics including membrane blebbing, condensation of nuclear chromatin, DNA fragmentation, and, even with the overexpression of bcl-2, release of cytochrome c from the mitochondria into the cytoplasm.
Ordinarily, Bcl-2 acts upstream of mitochondrial caspase activation to prevent apoptosis (Shimizu et al., 1996; Chinnaiyan et al., 1996; Okuno et al., 1998) . However, our recent studies have demonstrated that, in cells that express caspase 3, NCS treatment leads to the conversion of Bcl-2 to its proapoptotic fragment (Liang et al., 2001) , and this, in turn, lifts the impediment to apoptosis imposed by Bcl-2 and potentiates apoptosis enactment (Cheng et al., 1997; Kirsch et al., 1999) . In contrast, NCS treatment of mock-or bcl-2-transfected, caspase 3-de®cient MCF-7 cells does not result in cleavage of Bcl-2. In fact, bcl-2 transfection shifts the NCS concentration-response curve of MCF-7 cells in the direction of resistance to apoptosis induction (Schor et al., 2000) . Nonetheless, suciently high concentrations of NCS induce apoptosis in bcl-2-transfected MCF-7 cells that is morphologically and biochemically indistinguishable from that seen in native and mock-transfected MCF-7 cells. NCS-induced apoptosis in bcl-2-transfected MCF-7 cells is accompanied by decreased levels of Bcl-2 and increased levels of Bax. Under these circumstances, the mitochrondrial membrane PT pore opens (Susin et al., 1999) and cytochrome c is released. This, in turn, leads to caspase activation.
It has been suggested that caspase 3 activation is a critical initial event in the apoptosis enactment caspase cascade (Oberhammer et al., 1993; Eck-Enriquez et al., 2000) . In this cascade, cytochrome c, normally sequestered in the mitochondrial intermembrane space, is released through the mitochondrial outer membrane early during apoptosis (Liu et al., 1996) and interacts with Apaf-1, dATP (or ATP), and procaspase 9, culminating in the proteolytic activation of the caspase 9 zymogen (Li et al., 1997; Zou et al., 1997) . Activated caspase 9 activates procaspase 3 (Li et al., 1997) , and caspase 3, in turn, activates a DNA fragmentation factor (DFF)/caspase-activated DNase (CAD), which ®nally induces DNA fragmentation Enari et al., 1998) . That MCF-7 cells undergo morphological and physiological apoptosis suggests the presence of an alternative enactment pathway. It has, in fact, been proposed that initiator caspases with long prodomains, such as caspase 8 or 9, can lead to apoptosis enactment through activation not only of caspase 3, but of caspase 7 as well (Cohen, 1997; Fraser and Evan, 1996; Srinivasula et al., 1996) .
In order to explore the caspase cascade responsible for NCS-induced apoptosis in mock-and bcl-2-transfected MCF-7 cells, we examined the eects of selective caspase inhibitors on apoptosis enactment in this system. The caspase cascade implicated did not dier between the two transfectants. We ®rst examined the upstream caspases, caspases 8 and 9. Inhibition of caspase 8 and granzyme B did not protect MCF-7 cells from NCS-induced apoptosis. In contrast, inhibition of caspases 4, 5 and 9 results in protection of MCF-7 cells from NCS-induced apoptosis. Since inhibition of caspases 4 and 5 had no Figure 4 Inhibitors of caspases 1, 5, and 8 did not protect MCF-7 cells from NCS-induced apoptosis. bcl-2-transfected MCF-7 cells were incubated with 10, 25 or 100 mM of each caspase inhibitor, respectively, for 2 h before NCS treatment. The cells were then washed and incubated with fresh medium on day 0. Cells were counted daily as we have previously described (Schor, 1992; Hartsell et al., 1995 Hartsell et al., , 1996 Cortazzo and Schor, 1996) . Results are plotted as a per cent of the day 0 count for that condition+s.e.m. protective eect on NCS-treated MCF-7 cells, the protective eect seen with simultaneous inhibition of caspases 4, 5 and 9 must result from interference with the function of caspase 9.
Inhibition of the downstream caspase, caspase 7, protects MCF-7 cells from NCS-induced apoptosis. Caspase 7 is highly related to caspase 3 and shows the same synthetic substrate speci®city in vitro (Talanian et al., 1997) . Another downstream caspase, caspase 6, is responsible for the cleavage of the nuclear lamins , which, in turn, trigger cell death. Our results show that inhibition of caspase 6 is protective from apoptosis in our model, and suggests that caspase 6 is involved in NCS-induced apoptosis in MCF-7 cells.
Using assays for caspase activation, we examined the temporal sequence of activation of caspases 6, 7 and 9 in this pathway. Caspase 9 was ®rst activated 15 min after NCS treatment, while caspase 7 was not activated until 1 h after NCS treatment. Caspase 6 activity rose slowly starting at 2 h after NCS treatment, and continued to rise 6 h after NCS treatment was completed.
P21, the product of the p21 waf1/cip1 gene, is a cdk inhibitor that plays a critical role in regulating cell cycle progression. It has been implicated in mediating growth arrest in response to a variety of conditions associated with DNA damage, cell dierentiation, or growth factor de®ciency (El-Deiry et al., 1993; Parker et al., 1995) . Modulation of expression of p21 waf1/cip1 can be P53-dependent or P53-independent (Park et al., 2001 ). P53 was not detected in the MCF-7 cells used in the present experiments. P21 was up-regulated independent of P53; furthermore, P21 up-regulation followed modulation of the Bcl-2/Bax ratio after NCS treatment, making it a likely consequence or late facilitator of apoptosis enactment.
Taken together, the most likely sequence of events responsible for NCS-induced apoptosis in MCF-7 cells is diagrammed in Figure 6 . Decreased levels of Bcl-2 and increased levels of Bax allow opening of the mitochondrial PT pore with consequent cytochrome c release. This is true even in bcl-2-transfected MCF-7 cells, implying that the inhibition of cytochrome c release by Bcl-2 is a concentration-dependent, rather than an all-or-none phenomenon. Activation of caspase 9 follows and induces sequential activation of caspase 7 and caspase 6, respectively, which induces apoptosis in these cells. Figure 5 Inhibitors of caspases 6, 7 and 9 have a protective eect on NCS-treated MCF-7 cells. bcl-2 transfected MCF-7 cells were incubated with 10, 25 or 100 mM of each caspase inhibitor, respectively, for 2 h before NCS treatment. The cells were then washed and incubated with fresh medium on day 0. Cells were counted daily as we have previously described (Schor, 1992; Hartsell et al., 1995 Hartsell et al., , 1996 Cortazzo and Schor, 1996) . Results are plotted as a per cent of the day 0 count for that condition+s. 
Materials and methods
Cells and cell culture
Mock-and bcl-2 gene-transfected MCF-7 human breast cancer cells were the kind gift of Dr Charles Rudin (Department of Medicine, Northwestern University, Chicago, IL, USA; Schor et al., 2000) . These MCF-7 cell transfectants were generated by electroporation (300 mV, 960 mFD) with pSEEV-neomycin and pSFFV-bcl-2 (plasmids described in Boise et al., 1993) , respectively. Stably transfected MCF-7 clones were screened for Bcl-2 production by Western blot analysis using N-19 anti-Bcl-2 antibody (Santa Cruz Biotechnology). The results of single determinations from each of one mock-(neo.1-mock) and one bcl-2-transfected (bcl-2.3) clone of MCF-7 cells were used. These MCF-7 transfectants were maintained as adherent monolayers in 75-mm 2 culture¯asks (Life Technologies, Grand Island, NY, USA) and fed twice weekly with a-MEM (Mediatech, Herndon, VA, USA) supplemented with 5% fetal bovine serum, 0.3% glucose, 2 mM L-glutamine (Life Technologies, Grand Island, NY, USA), and 2 mg/ml gentamicin sulfate (Bio¯uids, Rockville, MD, USA).
NCS treatment
Mock-or bcl-2-transfected MCF-7 cells were treated with either 50 nM NCS (Kayaku Pharmaceuticals Ltd., Japan) or vehicle for 1 h. Subsequently, the cells were washed twice with and maintained in fresh medium. For studies involving treatment with caspase inhibitors, 10, 25 or 100 mM inhibitor was added 2 h prior to NCS treatment and maintained in the medium for the duration of the experiment. All caspase a b Figure 6 (a) Caspase 6 and caspase 9 activity in MCF-7 cells after NCS (50 nM) treatment. Two hundred mg cell lysate were used for analysis. After adding reaction buer and VEID-pNA (caspase 6) or LEHD-pNA (caspase 9) substrate, the samples were incubated at 378C for 1 h. The OD of the samples was read at 405 nm in a microtiter plate reader. Fold-increase in caspase 6 or 9 activity was determined by comparing these results with the OD 405nm of vehicle-treated controls. Background readings from cell lysate and buers were subtracted from the OD obtained in the case of each sample. A: caspase 6 activity; B: caspase 9 activity. Results are shown from a single representative experiment of three performed. (b) Western blot analysis of caspase 7 activity in NCS (50 nM) -treated bcl-2-transfected MCF-7 cells. MCF-7 cells were treated with NCS (50 nM; 1 h). At various time points after completion of NCS treatment, the cells were harvested and lysed for Western blot analysis. One hundred mg of total protein were added to each lane. Results of staining with anti-caspase 7 antibodies (Cell Signaling Technology) are shown. Results are shown from a single representative experiment of three performed Figure 7 Schematic of proposed apoptosis cascade in MCF-7 cells. Decreased Bcl-2 and increased Bax levels after NCS treatment induce the release of cytochrome c (stars) from the mitochondria. Cytochrome c activates caspase 9, which in turn activates caspase 7. Activated caspase 7 activates caspase 6, which induces apoptosis in MCF-7 cells, presumably through cleavage of nuclear lamins inhibitors (Z-VAAD-FMK, Ac-VAD-CHO, Ac-AAVALL-PAVLLALLAP-YVAD-CHO, Ac-AAVALLPAVLLAL-LAP-IETD-CHO, Ac-AAVALLPAVLLALLAP-VEID-CHO, Ac-AAVALLPAVLLALLAP-LEHD-CHO, Z-WEHD-FMK) were purchased from Oncogene Science, Inc. Adherent cell number was determined in triplicate daily in control and treated cultures, as we have described previously for neuroblastoma cells (Schor, 1992; Hartsell et al., 1995 Hartsell et al., , 1996 Cortazzo and Schor, 1996) . The statistical signi®cance of dierences between control and treated cultures was assessed in all cases using Student's t-test, with P40.05 being considered signi®cant.
Western blotting analysis of Bcl-2, Bax, caspase 7, P21, and P53
At the indicated time points, MCF-7 cells were lysed in RIPA buer (10 mM Tris, pH 8, 150 mM NaCl, 0.1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 4 mg/ml aprotinin, 1 mM sodium orthovanadate). Subsequently, the protein concentration was estimated in triplicate samples using the Bio-Rad protein assay (Bio-Rad Laboratories, CA, USA) with bovine serum albumin as a standard. A lysate of A431 cells (Santa Cruz Biotechnology), used as a positive control for P53, was treated in the same manner. Onehundred mg of protein was loaded in each lane of a 15% SDS-polyacrylamide gel and electrophoresed followed by blotting onto a nitrocellulose membrane (Bio-Rad Laboratories). After blotting, non-speci®c binding was blocked by 5% non-fat dry milk in PBS and the membrane was incubated for 2 h at 208C with either anti-Bcl-2 (1 : 500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Bax (1 : 500; Santa Cruz Biotechnology), anti-caspase 7 (1 : 1000; Cell Signaling Technology, Beverly, MA, USA), anti-P21 (F-5; 1 : 1000; Santa Cruz Biotechnology), or anti-P53 (Pab 240; Santa Cruz Biotechnology) antibodies diluted into 5% nonfat dry milk in PBS, washed, and incubated with secondary horseradish peroxidase conjugated anti-mouse IgG antibody or anti-rabbit IgG (Santa Cruz Biotechnology) for 1 h. The membrane was ®nally washed and developed with Western blotting chemiluminescence luminol reagent (Santa Cruz Biotechnology) following the manufacturer's instructions.
Isolation of mitochondria and detection of cytochrome c release MCF-7 cells were harvested by centrifugation at 600 g for 10 min at 48C. The cell pellets were washed once with icecold PBS and resuspended in ®ve volumes of buer A (20 mM HEPES ± KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol and 0.1 mM phenylmethylsulfonyl¯uoride) containing 250 mM sucrose. The cells were homogenized with 25 strokes of a Polytron homogenizer (Kinematica, Switzerland), and the homogenates were centrifuged twice at 750 g for 10 min at 48C. The supernatants were centrifuged at 10 000 g for 15 min at 48C, and the resulting mitochondrial pellets were resuspended in buer A containing 250 mM sucrose and frozen as multiple aliquots at 7208C. The supernatants of the 10 000 g spin were further centrifuged at 100 000 g for 20 min at 48C, and the resulting supernatants were divided into aliquots and frozen at 7208C for further experiments.
Fifty mg of mitochondria and 100 mg of supernatant were used for detection of cytochrome c by Western blotting analysis. Anti-cytochrome c antibodies were purchased from PharMingen International Company and used for Western blotting at a dilution of 1 : 1000.
Flow cytometric analysis of apoptotic cells
Apoptotic cells were quanti®ed by¯ow cytometry considering 7-AAD staining intensity to be proportional to the DNA content (Lecoeur and Gougeon, 1996) . Saponin and 7-aminoactinomycin D (7-AAD) were purchased from Sigma Chemical Corporation (St. Louis, MO, USA). In short, after harvesting, the cells were washed once in PBS and once in PBS/0.05% saponin, followed by addition of 4 mg 7-AAD in 1 ml PBS/saponin to the samples. The cells were incubated at room temperature in the dark for 30 min, and DNA histograms were obtained using a CellQuest apparatus and CellQuest software (Becton Dickinson). Data on 10 4 cells were collected. Electronic gates were set for viable and apoptotic cells with 2N ± 4N DNA and subnormal DNA contents, respectively, and for exclusion of debris. Per cent apoptosis was calculated as (number of apoptotic cells/ number of total cells)6100.
DNA staining with propidium iodide (PI)
Monolayers of mock-and bcl-2-transfected MCF-7 cells grown on coverslips were treated with 50 nM NCS for 1 h. The NCS was then washed away and fresh medium was added to the cells. After various lengths of time, the cells were washed with PBS and ®xed with cold ethanol (95%) for 5 min. After again washing with PBS, the cells were treated with RNase (1 mg/ml) for 1 h at 378C. The cells were then stained with PI (20 ng/ml) for 5 min and the coverslips were mounted on slides with Gelvatol. A Zeiss light microscope equipped for epi¯uorescent illumination was used for all observations.
Immunostaining of Bcl-2 and Bax protein
Monolayers of MCF-7 cells grown on coverslips were treated with 50 nM NCS for 1 h. After incubation various lengths of time, the cells were ®xed in situ with cold ethanol (95%) for 5 min and washed three times with Tris-buered saline (TBS)/Triton X-100. The cells were incubated in PBS containing 0.25% bovine serum albumin and 10% horse serum for 30 min to reduce nonspeci®c binding. The cells were then incubated with anti-Bcl-2 (1 : 200) or anti-Bax (1 : 1000) antibodies (both from Santa Cruz) at 48C overnight. The cells were washed in TBS/Triton X-100 three times for 10 min each and then incubated for 1 h at room temperature with a 1 : 200 dilution of rabbit anti-mouse Cy TM 2 immunoconjugate (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). The cells were washed in TBS/ Triton X-100 three times (10 min each wash) and incubated with goat anti-rabbit immunoconjugate (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) Cy TM 3 for 1 h at room temperature. The cells were again washed with TBS/Triton X-100 three times. The coverslips were mounted with Gelvatol. A Zeiss light microscope equipped for epi¯uorescent illumination was used for observation. For assessment of nonspeci®c immunostaining, alternating sister culture coverslips were incubated without primary antibody.
Caspase 6 and Caspase 9 colorimetric protease assay At dierent time points, MCF-7 cells were harvested according to the directions accompanying the protease assay kit (Medical and Biological Laboratory Co. Ltd, Naka-ku, Japan) and assayed for caspase 6 and 9 activities using the manufacturer's instructions. Brie¯y, 200 mg of protein in cell lysate were used for the analysis. The volume of cell lysate was adjusted to 50 ml with lysis buer, and 50 ml of 26reaction buer was added to each sample. Five ml of 4 mM VEID ± pNA (for caspase 6) or 5 ml of LEHD ± pNA (for caspase 9) were added, and the samples were incubated at 378C for 1 h. The OD at 405 nm was read in a microtiter plate reader. Fold-increase in caspase 6 or 9 activity over control samples was determined by comparing these results with the OD 405nm of a simultaneously incubated control (i.e., vehicle-rather than NCS-treated) sample. The background reading from cell lysates and buers was subtracted from the readings of both NCS-treated and control samples before calculating fold increase in caspase 6 or 9 activity.
